Study shows liraglutide results in increased insulin sensitivity independent of weight loss

Study links gene network and pancreatic beta cell defects to Type 2 diabetes

A comprehensive study that integrates multiple analytic approaches has linked a regulatory gene network and functional defects in insulin-producing pancreatic beta cells to Type 2 diabetes.

Powers receives prestigious Veterans Affairs Middleton Award

Alvin C. Powers, MD, Joe C. Davis Professor of Biologic Science and professor of Medicine, Molecular Physiology and Biophysics, has received the 2023 William S. Middleton Award, the highest honor awarded by the Department of Veterans Affairs (VA) Biomedical Laboratory Research and Development Service.

Powers announces plan to step down from key diabetes leadership roles

Alvin C. Powers, MD, has announced plans to step down effective July 1, 2024, as director of the Vanderbilt Diabetes Center, director of the Vanderbilt Diabetes Research and Training Center, and chief of the Division of Diabetes, Endocrinology and Metabolism.

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.